Pidilizumab
Product Specifications
UNSPSC Description
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].
Target Antigen
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pidilizumab.html
Solubility
10 mM in DMSO
Smiles
[Pidilizumab]
References & Citations
[1]Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77.|[2]Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P990077/Pidilizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P990077/
Clinical Information
Phase 2
CAS Number
1036730-42-3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
